SGLT2 Inhibitors and the Risk of Acute Kidney Injury in Older Adults With Type 2 Diabetes
- 8 November 2021
- journal article
- research article
- Published by Elsevier in American Journal of Kidney Diseases
- Vol. 79 (6) , 858-867.e1
Abstract
No abstract availableKeywords
Funding Information
- National Institute on Aging
This publication has 38 references indexed in Scilit:
- Use of the Medicare database in epidemiologic and health services research: a valuable source of real-world evidence on the older and disabled populations in the USClinical Epidemiology, 2017
- Nephron Protection in Diabetic Kidney DiseaseNew England Journal of Medicine, 2016
- Acute kidney injury from SGLT2 inhibitors: potential mechanismsNature Reviews Nephrology, 2016
- Empagliflozin and Progression of Kidney Disease in Type 2 DiabetesNew England Journal of Medicine, 2016
- Can a Shift in Fuel Energetics Explain the Beneficial Cardiorenal Outcomes in the EMPA-REG OUTCOME Study? A Unifying HypothesisDiabetes Care, 2016
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 DiabetesNew England Journal of Medicine, 2015
- Excess Mortality among Persons with Type 2 DiabetesNew England Journal of Medicine, 2015
- Acute SGLT inhibition normalizes O2tension in the renal cortex but causes hypoxia in the renal medulla in anaesthetized control and diabetic ratsAmerican Journal of Physiology-Renal Physiology, 2015
- Metrics for covariate balance in cohort studies of causal effectsStatistics in Medicine, 2013
- Validity of International Classification of Diseases, Ninth Revision, Clinical Modification Codes for Acute Renal FailureJournal of the American Society of Nephrology, 2006